A. Villegas

发表

Durvalumab after Chemoradiotherapy in Stage III Non–Small‐Cell Lung Cancer

Tarek Mekhail, Maike de Wit, Kaoru Kubota, 2017, The New England journal of medicine.

Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC).

M. Socinski, Keunchil Park, P. Dennis, 2021, Clinical lung cancer.

Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC

D. Planchard, C. Faivre-Finn, L. Paz-Ares, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Outcomes with durvalumab by tumour PD-L1 expression in unresectable, Stage III non-small-cell lung cancer in the PACIFIC trial.

D. Planchard, C. Faivre-Finn, S. Senan, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Three-year overall survival update from the PACIFIC trial.

D. Planchard, C. Faivre-Finn, L. Paz-Ares, 2019, Journal of Clinical Oncology.

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

D. Planchard, C. Faivre-Finn, L. Paz-Ares, 2018, The New England journal of medicine.

Hypokalemic Paralysis Secondary to Immune Checkpoint Inhibitor Therapy

A. Villegas, Pragathi Balakrishna, 2017, Case reports in oncological medicine.

MA05.02 PACIFIC Subgroup Analysis: Pneumonitis in Stage III, Unresectable NSCLC Patients Treated with Durvalumab vs. Placebo After CRT

C. Faivre-Finn, J. Vansteenkiste, P. Dennis, 2018, Journal of Thoracic Oncology.

Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non–Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers

L. Bubendorf, R. Stahel, S. Peters, 2018, Clinical Cancer Research.

Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC).

C. Faivre-Finn, S. Senan, L. Paz-Ares, 2020, Lung cancer.

Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study.

P. Dennis, B. Cho, Yiduo Zhang, 2019, The Lancet. Oncology.

COVID-19: A Rare Cause of Hemolytic Uremic Syndrome

A. Villegas, Kimberly Boldig, R. Batra, 2022, Cureus.

Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial

S. Senan, Y. Wu, H. Mann, 2022, ESMO open.

LBA1_PRPACIFIC: A double-blind, placebo-controlled phase III study of durvalumab after chemoradiation therapy (CRT) in patients with stage III, locally advanced, unresectable NSCLC

D. Planchard, L. Paz-Ares, P. Dennis, 2017 .

Efficacy of durvalumab in patients with stage III NSCLC who experience pneumonitis (PACIFIC)

C. Faivre-Finn, J. Vansteenkiste, P. Dennis, 2019, Annals of Oncology.

Efficacy, safety, and biomarker results of trastuzumab emtansine (T-DM1) in patients (pts) with previously treated HER2-overexpressing locally advanced or metastatic non-small cell lung cancer (mNSCLC).

L. Bubendorf, R. Stahel, S. Peters, 2017 .

Intramedullary Spinal Cord Metastasis in Breast Cancer: Clinical Features, Diagnosis, and Therapeutic Consideration

T. Guthrie, A. Villegas, 2004, The breast journal.

Three-year overall survival update from the PACIFIC trial

D. Planchard, C. Faivre-Finn, L. Paz-Ares, 2019, Annals of Oncology.

Efficacy and safety evaluation based on time from completion of radiotherapy to randomization with durvalumab or placebo in pts from PACIFIC.

C. Faivre-Finn, S. Senan, D. Raben, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.